<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>PharmaceuticalSovereignty.com ‚Äî Critical Medicines & Supply Chain Resilience</title>
  <meta name="description" content="PharmaceuticalSovereignty.com ‚Äî independent descriptive .com domain for pharmaceutical sovereignty: critical medicines, shortages, supply chain resilience, manufacturing capacity and collaborative procurement. Neutral banner for future frameworks, alliances or observatories." />

  <!-- Canonical & hreflang -->
  <link rel="canonical" href="https://www.pharmaceuticalsovereignty.com/" />
  <link rel="alternate" href="https://www.pharmaceuticalsovereignty.com/" hreflang="fr" />
  <link rel="alternate" href="https://www.pharmaceuticalsovereignty.com/" hreflang="en" />
  <link rel="alternate" href="https://www.pharmaceuticalsovereignty.com/" hreflang="x-default" />
  <meta name="robots" content="index,follow,max-image-preview:large" />

  <!-- Open Graph / Twitter -->
  <meta property="og:title" content="PharmaceuticalSovereignty.com ‚Äî Critical Medicines & Supply Chain Resilience" />
  <meta property="og:description" content="Independent, descriptive .com domain reserved as a neutral banner for critical medicines, pharmaceutical shortages and supply chain resilience frameworks, alliances and observatories." />
  <meta property="og:url" content="https://www.pharmaceuticalsovereignty.com/" />
  <meta property="og:type" content="website" />
  <meta property="og:image" content="https://www.pharmaceuticalsovereignty.com/og.jpg" />
  <meta property="og:image:alt" content="PharmaceuticalSovereignty.com ‚Äî descriptive asset for pharmaceutical sovereignty and critical medicines" />

  <meta name="twitter:card" content="summary_large_image" />
  <meta name="twitter:image" content="https://www.pharmaceuticalsovereignty.com/og.jpg" />

  <!-- Icons & preload -->
  <link rel="icon" href="/favicon.ico" />
  <link rel="apple-touch-icon" href="/apple-touch-icon.png" />
  <link rel="preload" as="image" href="/logo-pharmaceuticalsovereignty.png" imagesizes="260px" />

  <!-- Structured data -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "WebSite",
    "name": "PharmaceuticalSovereignty.com",
    "url": "https://www.pharmaceuticalsovereignty.com/",
    "inLanguage": ["en-GB","en-US","fr-FR"],
    "description": "Independent, descriptive digital asset for pharmaceutical sovereignty: critical medicines, shortages, supply chain resilience, manufacturing capacity and collaborative procurement.",
    "sameAs": ["https://www.linkedin.com/company/pharmaceuticalsovereignty"],
    "potentialAction": {
      "@type": "CommunicateAction",
      "target": "mailto:contact@pharmaceuticalsovereignty.com"
    }
  }
  </script>

  <!-- Styles (same base as NatureRisk.org) -->
  <style>
    :root{
      --bg:#020815;
      --card:#081120;
      --muted:#8791b0;
      --text:#e8eefc;
      --accent:#7fd0ff;
      --chip:#101b34;
      --shadow:0 10px 30px rgba(0,0,0,.45);
      --radius:18px;
    }
    *{box-sizing:border-box}
    html,body{
      margin:0;
      padding:0;
      background:var(--bg);
      color:var(--text);
      font:15px/1.6 system-ui,-apple-system,Segoe UI,Roboto,Inter,Ubuntu,Arial,sans-serif;
      -webkit-font-smoothing:antialiased;
    }
    a{color:var(--accent);text-decoration:none}
    a:hover{text-decoration:underline}
    .wrap{max-width:1040px;margin:0 auto;padding:28px}
    .topbar{
      display:flex;
      justify-content:space-between;
      align-items:center;
      margin:8px 0 22px;
      gap:12px;
      flex-wrap:wrap;
    }
    .badge{
      display:inline-flex;
      align-items:center;
      gap:8px;
      background:var(--chip);
      border:1px solid #1d2946;
      border-radius:999px;
      padding:6px 12px;
      color:#c1ccec;
      font-size:13px;
    }
    .badge-dot{
      width:8px;
      height:8px;
      border-radius:999px;
      background:radial-gradient(circle,#4ade80 0,#16a34a 55%,#052e16 100%);
      box-shadow:0 0 0 6px rgba(34,197,94,.25);
    }
    .lang{
      gap:10px;
      display:flex;
      align-items:center;
    }
    .lang button{
      background:var(--chip);
      color:var(--text);
      border:1px solid #1d2946;
      padding:7px 12px;
      border-radius:999px;
      cursor:pointer;
      font-size:13px;
    }
    .lang button[aria-pressed="true"]{
      background:var(--accent);
      color:#020815;
      border-color:transparent;
    }
    .card{
      background:var(--card);
      border:1px solid #1d2946;
      border-radius:var(--radius);
      padding:26px;
      box-shadow:var(--shadow);
    }
    .hero h1{
      margin:0 0 8px;
      font-size:44px;
      letter-spacing:.4px;
    }
    .cta{
      display:flex;
      gap:12px;
      flex-wrap:wrap;
      margin:18px 0 6px;
    }
    .btn{
      display:inline-flex;
      align-items:center;
      gap:8px;
      background:#122143;
      color:#fff;
      border:1px solid #21325b;
      padding:11px 16px;
      border-radius:999px;
      cursor:pointer;
      text-decoration:none;
      font-size:14px;
    }
    .btn.primary{
      background:var(--accent);
      color:#020815;
      border-color:transparent;
    }
    .btn.btn-concept{
      background:transparent;
      color:var(--accent);
      border-radius:999px;
      border:1px solid rgba(143,176,255,0.85);
      box-shadow:0 0 0 1px rgba(2,8,21,0.9);
      padding:9px 16px;
      font-size:14px;
    }
    .btn.btn-concept:hover{
      text-decoration:none;
      background:rgba(143,176,255,0.06);
    }
    .btn.btn-concept .cn-icon{
      width:14px;
      height:14px;
      border-radius:4px;
      background:linear-gradient(135deg,#7fd0ff,#4a8dff);
      display:inline-block;
    }
    .grid{
      display:grid;
      grid-template-columns:repeat(12,1fr);
      gap:18px;
    }
    .col-6{grid-column:span 6}
    .col-12{grid-column:span 12}
    .chip{
      display:inline-block;
      background:var(--chip);
      border:1px solid #1d2946;
      border-radius:999px;
      padding:6px 10px;
      font-size:13px;
      color:#c1ccec;
    }
    .list{
      display:grid;
      gap:10px;
      margin:8px 0;
    }
    .muted{color:var(--muted)}
    .foot{opacity:.8;font-size:13px;margin-top:24px}
    img.logo{
      max-width:260px;
      height:auto;
      display:block;
      margin:10px 0 10px;
      opacity:.97;
      border-radius:14px;
    }
    @media (max-width:860px){
      .col-6{grid-column:span 12}
      .hero h1{font-size:34px}
    }
    .ico{width:16px;height:16px;display:inline-block;vertical-align:middle}
  </style>
</head>
<body>
  <div class="wrap">
    <div class="topbar">
      <div class="badge">
        <span class="badge-dot"></span>
        <span>Digital assets available for acquisition</span>
      </div>
      <div class="lang">
        <button id="btn-fr" aria-pressed="false">FR</button>
        <button id="btn-en" aria-pressed="true">EN</button>
      </div>
    </div>

    <!-- ============ HERO EN ============ -->
    <section class="card hero" data-en>
      <h1>PharmaceuticalSovereignty.com</h1>
      <img class="logo" src="/logo-pharmaceuticalsovereignty.png" alt="PharmaceuticalSovereignty.com" loading="eager">
      <p class="muted">
        <b>Descriptive .com domain</b> for the emerging doctrine of
        <b>‚Äúpharmaceutical sovereignty‚Äù</b>: securing the availability of critical
        medicines by strengthening manufacturing capacity, supply chain resilience,
        diversified sourcing of active pharmaceutical ingredients (APIs) and
        smarter public procurement.<br>
        PharmaceuticalSovereignty.com is reserved as a <b>neutral, non-promotional
        banner</b> for <b>frameworks, alliances, observatories or data hubs</b>
        dedicated to critical medicines, shortages and structural resilience of
        pharmaceutical supply chains.<br>
        It sits at the intersection of <b>industrial policy, public health and
        strategic procurement</b>, in line with debates on critical medicines lists,
        the EU Critical Medicines initiative and similar programmes in other
        jurisdictions.<br>
        Intended for <b>governments, public agencies, coalitions, pharmaceutical
        manufacturers, data providers and policy think tanks</b> that may wish, in
        the future, to operate a public-facing initiative under a clear, descriptive
        label.
      </p>
      <div class="cta">
        <a class="btn primary" href="mailto:contact@pharmaceuticalsovereignty.com?subject=PharmaceuticalSovereignty.com%20-%20NDA%20%2F%20Offer">
          Submit an offer / Request NDA
        </a>
        <a class="btn btn-concept" href="/concept-note.html">
          <span class="cn-icon"></span>
          Concept Note
        </a>
        <a class="btn" href="#value-en">Why this name?</a>
        <a class="btn" href="https://www.linkedin.com/company/pharmaceuticalsovereignty" target="_blank" rel="noopener" aria-label="Open PharmaceuticalSovereignty.com on LinkedIn">
          <svg class="ico" viewBox="0 0 24 24" fill="currentColor" aria-hidden="true">
            <path d="M4.98 3.5C4.98 4.88 3.85 6 2.5 6S0 4.88 0 3.5 1.12 1 2.5 1s2.48 1.12 2.48 2.5zM.5 8.5h4V23h-4V8.5zM8.5 8.5h3.8v2h.05c.53-1 1.84-2.05 3.78-2.05 4.04 0 4.79 2.66 4.79 6.13V23h-4v-6.5z"/>
          </svg>
          LinkedIn
        </a>
      </div>
      <p class="muted" style="margin-top:8px">
        <b>Important notice:</b> PharmaceuticalSovereignty.com is a
        <b>descriptive semantic asset</b>. It is <b>not</b> an official portal of the
        European Union, the European Commission, EMA, HERA, WHO, any national
        ministry of health, medicines agency or pharmaceutical company. This site
        provides <b>no</b> medical, clinical or prescribing information, <b>no</b>
        pharmaceutical products, and <b>no</b> individual patient services. It does
        <b>not</b> offer legal, regulatory, investment or public health advice. Any
        future framework, alliance or observatory operating under this banner would
        be entirely designed and governed by its acquirer, under its own
        responsibilities and applicable laws.
      </p>
    </section>

    <!-- ============ VALUE EN ============ -->
    <section id="value-en" class="card" style="margin-top:16px" data-en>
      <div class="grid">
        <div class="col-6">
          <h3>Why PharmaceuticalSovereignty.com is valuable</h3>
          <div class="list">
            <div class="chip">Straightforward, board-level expression matching the language of ‚Äúpharmaceutical sovereignty‚Äù, ‚Äúcritical medicines‚Äù and ‚Äúshortage prevention‚Äù in policy debates.</div>
            <div class="chip">Neutral .com banner suitable for public-interest initiatives, coalitions or observatories, clearly separate from any single laboratory or vendor brand.</div>
            <div class="chip">Connects shortages, manufacturing capacity, diversified sourcing of APIs and strategic stockpiles under one descriptive label.</div>
            <div class="chip">Defensive semantic asset if ‚Äúpharmaceutical sovereignty‚Äù becomes a standard category in industrial, health security or procurement frameworks.</div>
            <div class="chip">Durable anchor for long-term programmes on critical medicines, resilience indicators and policy coordination across jurisdictions.</div>
          </div>
        </div>
        <div class="col-6">
          <h3>Illustrative use cases</h3>
          <div class="list">
            <div class="chip">Public-facing hub explaining pharmaceutical sovereignty, critical medicines lists and structural drivers of shortages in accessible language.</div>
            <div class="chip">Neutral entry point to critical medicines initiatives, supply chain resilience frameworks and collaborative procurement schemes.</div>
            <div class="chip">Indicator and scenario hub describing exposure to geographic concentration of manufacturing, API dependencies and logistics bottlenecks.</div>
            <div class="chip">External banner for a ‚ÄúCritical Medicines & Pharmaceutical Sovereignty Framework‚Äù connecting industrial policy, health security and procurement teams.</div>
            <div class="chip">Multi-stakeholder knowledge centre convening regulators, payers, manufacturers, wholesalers and patient representatives around critical medicines resilience.</div>
          </div>
        </div>
      </div>
      <p class="muted">
        This site does <b>not</b> sell medicines, medical devices, software, data,
        consulting or logistics services. It offers the
        <b>PharmaceuticalSovereignty.com</b> domain name as a descriptive digital
        asset. Any methodologies, portals, observatories or procurement platforms
        developed under this label would be created and validated independently by
        the acquirer, in line with its mandates and governance.
      </p>
    </section>

    <!-- ============ RELATED EN ============ -->
    <section class="card" style="margin-top:16px" data-en>
      <h3>Related assets (critical medicines, nature & transition themes)</h3>
      <p class="muted">
        Depending on its strategy, a future owner may decide to position
        <b>PharmaceuticalSovereignty.com</b> alongside other neutral banners focused
        on resilience and systemic risk:
      </p>
      <div class="list">
        <a class="chip" href="https://www.transitionrisk.org" target="_blank" rel="noopener">TransitionRisk.org</a>
        <a class="chip" href="https://www.naturerisk.org" target="_blank" rel="noopener">NatureRisk.org</a>
        <a class="chip" href="https://www.watersolvency.com" target="_blank" rel="noopener">WaterSolvency.com</a>
        <a class="chip" href="https://www.climatesolvency.com" target="_blank" rel="noopener">ClimateSolvency.com</a>
      </div>
      <p class="muted">
        These examples are illustrative only. This site offers for sale the
        <b>PharmaceuticalSovereignty.com</b> domain name as a standalone asset; any
        bundling or broader architecture would be determined solely by the acquirer.
      </p>
    </section>

    <!-- ============ ACQUISITION EN ============ -->
    <section class="card" style="margin-top:16px" data-en>
      <h3>Acquisition (secure process)</h3>
      <p class="muted">
        A typical institutional flow: <b>NDA ‚Üí strategic discussion ‚Üí formal offer
        ‚Üí escrow ‚Üí domain transfer</b>. The transaction focuses on the
        <b>PharmaceuticalSovereignty.com</b> domain name as an intangible digital
        asset. No software, datasets, methodologies, consultancy, lobbying or
        service layer are included unless explicitly agreed in a separate contract.
      </p>
      <a class="btn primary" href="mailto:contact@pharmaceuticalsovereignty.com?subject=PharmaceuticalSovereignty.com%20-%20NDA%20%2F%20Offer">
        Direct contact: contact@pharmaceuticalsovereignty.com
      </a>
    </section>

    <!-- ============ DOCS EN ============ -->
    <section class="card" style="margin-top:16px" data-en>
      <h3>Documents / Briefs</h3>
      <p class="muted">
        Detailed PharmaceuticalSovereignty.com acquisition brief (2025-11) available
        in English for Industrial Policy, Public Health, Procurement, Supply Chain,
        Risk and Strategy teams.
      </p>
      <div class="cta">
        <a class="btn" href="/Acquisition%20Brief%20-%20pharmaceuticalsovereignty-EN-202511.pdf" target="_blank" rel="noopener" type="application/pdf">
          üëÅÔ∏è Open Brief (EN)
        </a>
        <a class="btn primary" href="/Acquisition%20Brief%20-%20pharmaceuticalsovereignty-EN-202511.pdf" download="Acquisition-Brief-PharmaceuticalSovereignty-EN-202511.pdf" type="application/pdf">
          üì• Download (EN, PDF)
        </a>
      </div>
    </section>

    <!-- ============ HERO FR ============ -->
    <section class="card hero" data-fr hidden>
      <h1>PharmaceuticalSovereignty.com</h1>
      <img class="logo" src="/logo-pharmaceuticalsovereignty.png" alt="PharmaceuticalSovereignty.com" loading="eager">
      <p class="muted">
        Nom de domaine <b>descriptif en .com</b> pour la doctrine √©mergente de
        <b>¬´ souverainet√© pharmaceutique ¬ª</b> : s√©curisation de la disponibilit√©
        des m√©dicaments critiques gr√¢ce au renforcement des capacit√©s de
        production, de la r√©silience des cha√Ænes d‚Äôapprovisionnement, de la
        diversification des sources d‚ÄôAPI et de la conception des achats publics.<br>
        PharmaceuticalSovereignty.com est r√©serv√© comme <b>banni√®re neutre et non
        commerciale</b> pour des <b>cadres, alliances, observatoires ou hubs
        d‚Äôinformation</b> d√©di√©s aux m√©dicaments critiques, aux p√©nuries et √† la
        r√©silience structurelle des cha√Ænes pharmaceutiques.<br>
        Il se situe au croisement de la <b>politique industrielle, de la s√©curit√©
        sanitaire et des strat√©gies d‚Äôachat</b>, en coh√©rence avec les d√©bats sur
        les listes de m√©dicaments critiques, l‚Äôinitiative europ√©enne sur les
        m√©dicaments critiques et des programmes similaires dans d‚Äôautres
        juridictions.<br>
        Destin√© en priorit√© aux <b>autorit√©s publiques, agences, coalitions,
        industriels, fournisseurs de donn√©es et think tanks</b> susceptibles, √†
        terme, d‚Äôop√©rer une initiative publique sous une banni√®re claire et
        descriptive.
      </p>
      <div class="cta">
        <a class="btn primary" href="mailto:contact@pharmaceuticalsovereignty.com?subject=PharmaceuticalSovereignty.com%20-%20NDA%20%2F%20Proposition">
          Proposer une offre / Demander un NDA
        </a>
        <a class="btn" href="#value-fr">Pourquoi ce nom ?</a>
        <a class="btn" href="https://www.linkedin.com/company/pharmaceuticalsovereignty" target="_blank" rel="noopener" aria-label="Ouvrir la page LinkedIn PharmaceuticalSovereignty.com">
          <svg class="ico" viewBox="0 0 24 24" fill="currentColor" aria-hidden="true">
            <path d="M4.98 3.5C4.98 4.88 3.85 6 2.5 6S0 4.88 0 3.5 1.12 1 2.5 1s2.48 1.12 2.48 2.5zM.5 8.5h4V23h-4V8.5zM8.5 8.5h3.8v2h.05c.53-1 1.84-2.05 3.78-2.05 4.04 0 4.79 2.66 4.79 6.13V23h-4v-6.5z"/>
          </svg>
          LinkedIn
        </a>
      </div>
      <p class="muted" style="margin-top:8px">
        <b>Nota important :</b> PharmaceuticalSovereignty.com est un
        <b>actif s√©mantique descriptif</b>. Ce site n‚Äôest <b>pas</b> le portail
        officiel de la Commission europ√©enne, de l‚ÄôEMA, de HERA, de l‚ÄôOMS, d‚Äôun
        minist√®re de la sant√©, d‚Äôune agence du m√©dicament ou d‚Äôune entreprise
        pharmaceutique. Il ne fournit <b>aucune</b> information m√©dicale
        individuelle, ne vend <b>aucun</b> m√©dicament ou dispositif et ne propose
        <b>aucun</b> service √† des patients. Il ne d√©livre <b>aucun</b> avis
        juridique, r√©glementaire, financier ou de sant√© publique. Tout cadre,
        observatoire ou alliance op√©r√© sous cette banni√®re serait int√©gralement
        con√ßu et gouvern√© par son acqu√©reur, sous sa seule responsabilit√© et dans
        le respect de ses propres cadres juridiques.
      </p>
    </section>

    <!-- ============ VALUE FR ============ -->
    <section id="value-fr" class="card" style="margin-top:16px" data-fr hidden>
      <div class="grid">
        <div class="col-6">
          <h3>Pourquoi PharmaceuticalSovereignty.com a de la valeur</h3>
          <div class="list">
            <div class="chip">Expression imm√©diatement compr√©hensible par les d√©cideurs sur la ¬´ souverainet√© pharmaceutique ¬ª, les m√©dicaments critiques et la pr√©vention des p√©nuries.</div>
            <div class="chip">Banni√®re neutre en .com, adapt√©e √† une initiative d‚Äôint√©r√™t g√©n√©ral, une coalition ou un observatoire, clairement distincte de toute marque industrielle.</div>
            <div class="chip">Rassemble, sous un m√™me libell√©, p√©nuries, capacit√©s de fabrication, d√©pendances aux API et stocks strat√©giques.</div>
            <div class="chip">Actif s√©mantique d√©fensif si la ¬´ souverainet√© pharmaceutique ¬ª devient une cat√©gorie structurante des politiques industrielles et de s√©curit√© sanitaire.</div>
            <div class="chip">Point d‚Äôancrage durable pour des programmes de long terme sur les m√©dicaments critiques, les indicateurs de r√©silience et la coordination des politiques.</div>
          </div>
        </div>
        <div class="col-6">
          <h3>Exemples de cas d‚Äôusage</h3>
          <div class="list">
            <div class="chip">Portail p√©dagogique expliquant la souverainet√© pharmaceutique, les listes de m√©dicaments critiques et les causes structurelles des p√©nuries.</div>
            <div class="chip">Point d‚Äôentr√©e neutre vers les initiatives sur les m√©dicaments critiques, les cadres de r√©silience des cha√Ænes d‚Äôapprovisionnement et les dispositifs d‚Äôachats conjoints.</div>
            <div class="chip">Hub d‚Äôindicateurs et de sc√©narios d√©crivant l‚Äôexposition aux concentrations g√©ographiques de fabrication, aux d√©pendances en API et aux goulets d‚Äô√©tranglement logistiques.</div>
            <div class="chip">Banni√®re externe d‚Äôun ¬´ cadre m√©dicaments critiques & souverainet√© pharmaceutique ¬ª reliant politique industrielle, s√©curit√© sanitaire et achats.</div>
            <div class="chip">Centre de connaissances multi-acteurs r√©unissant autorit√©s, payeurs, industriels, grossistes et repr√©sentants de patients autour de la r√©silience pharmaceutique.</div>
          </div>
        </div>
      </div>
      <p class="muted">
        Ce site ne vend <b>ni m√©dicament, ni dispositif m√©dical, ni logiciel, ni
        donn√©es, ni conseil</b>. Il propose le <b>nom de domaine
        PharmaceuticalSovereignty.com</b> en tant qu‚Äôactif num√©rique descriptif.
        Toute m√©thodologie, plateforme, alliance ou observatoire mis en place sous
        cette banni√®re rel√®vera int√©gralement de l‚Äôacqu√©reur, selon ses mandats et
        sa gouvernance.
      </p>
    </section>

    <!-- ============ AUTRES ACTIFS FR ============ -->
    <section class="card" style="margin-top:16px" data-fr hidden>
      <h3>Actifs associ√©s (m√©dicaments critiques, climat, nature)</h3>
      <p class="muted">
        Selon sa strat√©gie, un acqu√©reur pourra articuler
        <b>PharmaceuticalSovereignty.com</b> avec d‚Äôautres banni√®res neutres
        d√©di√©es aux risques syst√©miques et √† la r√©silience :
      </p>
      <div class="list">
        <a class="chip" href="https://www.transitionrisk.org" target="_blank" rel="noopener">TransitionRisk.org</a>
        <a class="chip" href="https://www.naturerisk.org" target="_blank" rel="noopener">NatureRisk.org</a>
        <a class="chip" href="https://www.watersolvency.com" target="_blank" rel="noopener">WaterSolvency.com</a>
        <a class="chip" href="https://www.climatesolvency.com" target="_blank" rel="noopener">ClimateSolvency.com</a>
      </div>
      <p class="muted">
        Ces exemples sont fournis √† titre illustratif. Sur ce site, seul le nom de
        domaine <b>PharmaceuticalSovereignty.com</b> est propos√© √† l‚Äôacquisition ;
        toute logique de bundle ou d‚Äôarchitecture restera √† la discr√©tion de
        l‚Äôacqu√©reur.
      </p>
    </section>

    <!-- ============ ACQUISITION FR ============ -->
    <section class="card" style="margin-top:16px" data-fr hidden>
      <h3>Acquisition (process s√©curis√©)</h3>
      <p class="muted">
        Processus type : <b>NDA ‚Üí √©changes strat√©giques ‚Üí offre formelle ‚Üí
        escrow ‚Üí transfert du domaine</b>. La transaction porte sur le
        <b>nom de domaine PharmaceuticalSovereignty.com</b> en tant qu‚Äôactif
        num√©rique incorporel. Aucun logiciel, base de donn√©es, m√©thodologie,
        lobbying, conseil ou service n‚Äôest inclus, sauf accord s√©par√© explicite.
      </p>
      <a class="btn primary" href="mailto:contact@pharmaceuticalsovereignty.com?subject=PharmaceuticalSovereignty.com%20-%20NDA%20%2F%20Proposition">
        Contact direct : contact@pharmaceuticalsovereignty.com
      </a>
    </section>

    <!-- ============ DOCS FR ============ -->
    <section class="card" style="margin-top:16px" data-fr hidden>
      <h3>Documents / Briefs</h3>
      <p class="muted">
        Brief d‚Äôacquisition d√©taill√© PharmaceuticalSovereignty.com (2025-11)
        disponible en fran√ßais pour les √©quipes Politique industrielle, Sant√©
        publique, Achats, Supply chain, Risques et Strat√©gie.
      </p>
      <div class="cta">
        <a class="btn" href="/Acquisition%20Brief%20-%20pharmaceuticalsovereignty-202511.pdf" target="_blank" rel="noopener" type="application/pdf">
          üëÅÔ∏è Ouvrir le Brief (FR)
        </a>
        <a class="btn primary" href="/Acquisition%20Brief%20-%20pharmaceuticalsovereignty-202511.pdf" download="Acquisition-Brief-PharmaceuticalSovereignty-FR-202511.pdf" type="application/pdf">
          üì• T√©l√©charger (FR, PDF)
        </a>
      </div>
    </section>

    <p class="foot muted">
      ¬© PharmaceuticalSovereignty.com ‚Äî descriptive digital asset ‚Äúpharmaceutical
      sovereignty‚Äù and critical medicines resilience. No affiliation with the
      European Union, European Commission, EMA, HERA, WHO, national authorities,
      regulators, public institutions or private companies. Descriptive use only.
      No medical, legal, regulatory, financial or investment advice. ‚Äî Contact:
      <a href="mailto:contact@pharmaceuticalsovereignty.com">contact@pharmaceuticalsovereignty.com</a>
    </p>
  </div>

  <script>
    const frBtn = document.getElementById('btn-fr');
    const enBtn = document.getElementById('btn-en');

    function show(lang){
      document.querySelectorAll('[data-fr]').forEach(n => n.hidden = (lang !== 'fr'));
      document.querySelectorAll('[data-en]').forEach(n => n.hidden = (lang !== 'en'));
      frBtn.setAttribute('aria-pressed', String(lang === 'fr'));
      enBtn.setAttribute('aria-pressed', String(lang === 'en'));
      document.documentElement.lang = lang;
    }

    frBtn.addEventListener('click', () => show('fr'));
    enBtn.addEventListener('click', () => show('en'));

    (function initLang(){
      show('en');
    })();
  </script>
</body>
</html>
